June 20, 2019 -- McKesson is now a nonexclusive distributor of Qiagen's QIAstat-Dx syndromic system for respiratory and gastrointestinal diseases in smaller U.S. hospitals, and it is also managing sales in nonacute retail pharmacies.
The QIAstat-Dx respiratory panel for detecting more than 20 respiratory viral and bacterial pathogens was cleared by the U.S. Food and Drug Administration (FDA) in May for use with the QIAstat-Dx syndromic testing system.
McKesson and Qiagen are targeting smaller facilities. There are approximately 2,000 hospitals in the U.S. with 200 or fewer beds, accounting for about 10% of the total market for syndromic testing nationally and $650 million in annual sales, according to the companies.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current